Scarica l'app Stockscreener
84.03
0.85%
-0.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$84.83
Aprire:
$83.52
Volume 24 ore:
2.41M
Relative Volume:
0.49
Capitalizzazione di mercato:
$260.49B
Reddito:
$56.53B
Utile/perdita netta:
$8.32B
Rapporto P/E:
31.56
EPS:
2.6622
Flusso di cassa netto:
$8.49B
1 W Prestazione:
-1.09%
1M Prestazione:
+8.45%
6M Prestazione:
+25.44%
1 anno Prestazione:
+7.41%
Intervallo 1D:
$83.09
$84.42
Intervallo di 1 settimana:
$83.09
$85.88
Portata 52W:
$61.24
$86.57
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
83.99 | 263.92B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs - Benzinga
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Trump Locks In AstraZeneca Deal to Slash Medicaid Drug Prices -- Big Pharma Faces New Reality - GuruFocus
Pattern recognition hints at AstraZeneca PLC Depositary Receipt upsideWeekly Trend Recap & Smart Money Movement Tracker - newser.com
AstraZeneca PLC Depositary Receipt recovery potential after sell offNew Guidance & Safe Entry Point Identification - newser.com
AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Prod - GuruFocus
AstraZeneca Boosts U.S. Manufacturing with Texas Facility Expansion - MarketScreener
$445M expansion: AstraZeneca doubles Lokelma production at Coppell, adds 9,000 sq ft - Stock Titan
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance - BioPharma Dive
AstraZeneca opens expanded facility in Texas - breakingthenews.net
AstraZeneca’s US listing plan backed by key shareholder advisers - The Times
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Is AstraZeneca PLC Depositary Receipt stock ready for a breakoutMarket Sentiment Report & Daily Stock Trend Reports - newser.com
AstraZeneca reaches agreement with US government to reduce drug prices - Investing.com
Will breakout in AstraZeneca PLC Depositary Receipt lead to full recovery2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
AstraZeneca reaches agreement with US government to reduce drug prices By Investing.com - Investing.com South Africa
Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN) - The Globe and Mail
UBS Keeps Their Buy Rating on AstraZeneca (AZN) - The Globe and Mail
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary ReceiptJuly 2025 Reactions & Momentum Based Trading Ideas - newser.com
Barclays Says AstraZeneca's US Drug Pricing Deal 'Strategically Constructive' - 富途牛牛
Astrazeneca to lower US prices amid Trump squeeze - MarketScreener
Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power - TradingView
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Why AstraZeneca PLC Depositary Receipt stock remains undervaluedWeekly Stock Recap & Target Return Focused Picks - newser.com
How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Will AstraZeneca PLC Depositary Receipt bounce back from current supportJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
AstraZeneca (AZN) Agrees to Lower Drug Prices in the U.S. with S - GuruFocus
AstraZeneca's drug pricing deal with Trump far from clear result, say analysts - Proactive financial news
AstraZeneca inks Trump drug pricing deal amid tariff threats - Pharmaceutical Technology
AstraZeneca PLC (AZN) Stock Analysis: 6.2% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
AstraZeneca: Drug Pricing Agreement Mitigates Threats of Tariffs and Price Controls - Morningstar Canada
Vanguard Personalized Indexing Management LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Trending tickers: TSMC, AstraZeneca, Lloyds, Fresnillo and Canal+ - Yahoo
AstraZeneca confirms deal with US government on drug prices - MarketScreener
AstraZeneca reaches agreement with Trump to lower its prices in the US - MarketScreener
AstraZeneca agrees to offer US discounts in exchange for no tariffs - Proactive financial news
AstraZeneca to cut US drug prices in key White House deal - Sharecast.com
AstraZeneca : Agreement with US Govt to lower medicine prices - MarketScreener
Trump announces deal with AstraZeneca on drug prices, tariffs - MarketScreener
AstraZeneca Plc Reaches Agreement With Trump Administration To Cut US Drug Prices - DirectorsTalk Interviews
AstraZeneca Joins US President Trump's Drug-Cost Initiative, Secures Tariff Reprieve - MarketScreener
US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions - insights.citeline.com
President Trump announces deal with AstraZeneca on drug prices and tariffs - Taipei Times
Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump - MarketScreener
AstraZeneca PLC $AZN Shares Bought by Aberdeen Group plc - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Lowered by US Bancorp DE - MarketBeat
AstraZeneca Signs US Drug Pricing Deal, Secures Three-year Delay to Tariffs - MarketScreener
Target Identification and Validation In Drug Discovery - Oncodaily
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts - ts2.tech
Benson Investment Management Company Inc. Takes $4.44 Million Position in AstraZeneca PLC $AZN - MarketBeat
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):